Vor Bio Advances Telitacicept into Phase 3 Trial for Sjögren’s Disease
Event summary
- Vor Bio dosed the first patient in its global Phase 3 UPSTREAM SjD trial for telitacicept in primary Sjögren’s disease on March 30, 2026.
- The trial will enroll approximately 250 patients with active primary Sjögren’s disease, targeting a primary endpoint of change in ESSDAI score at Week 48.
- Telitacicept is the only BAFF/APRIL inhibitor in Phase 3 development for Sjögren’s disease, following prior Phase 3 results in China by RemeGen.
- Vor Bio aims to address a condition with no approved disease-modifying therapies, focusing on systemic disease activity and patient-reported symptoms.
The big picture
Vor Bio’s Phase 3 trial for telitacicept in Sjögren’s disease marks a critical step in addressing an underserved autoimmune condition with no approved disease-modifying therapies. The trial’s success could position telitacicept as a potential best-in-disease treatment, leveraging its dual BAFF/APRIL inhibition mechanism. The company’s global development strategy aims to expand its footprint beyond China, where telitacicept is already approved for other autoimmune diseases.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 trial results will support regulatory approvals in the U.S., Europe, and Japan, following its approval in China for other autoimmune diseases.
- Competitive Positioning
- How Vor Bio’s telitacicept will differentiate itself in a market lacking approved therapies for Sjögren’s disease.
- Execution Risk
- The pace at which Vor Bio can advance its global development programs across multiple autoimmune indications.